# North America CAR T-Cell Therapy Market Size, Share & Forecast, By Product Type, Disease Area & Country, 2026-2031 --- ## Market Overview # CHAPTER 1 - Market Overview The North America CAR T-Cell Therapy Market operates through a personalized manufacturing model in which patient T cells are collected, genetically modified, expanded and returned for infusion at specialist centers. The underlying demand pool remains substantial: leukemia, lymphoma and myeloma were projected to generate **192,070 new United States diagnoses in 2025**, sustaining referrals for relapsed and refractory disease. Commercial activity is concentrated in the United States, where referral networks, apheresis infrastructure and authorized centers support most regional infusions. Yescarta had access to **more than 150 authorized United States treatment centers**, while Carvykti was available through more than 140 activated centers. This concentration creates scale advantages in physician education, logistics coordination, intensive-care readiness and payer contracting. Regulatory access improved materially in June 2025 when the United States Food and Drug Administration removed Risk Evaluation and Mitigation Strategy requirements for approved autologous CAR T-cell products. The change eliminated mandatory REMS certification while preserving adverse-event reporting under **21 CFR 600.80**. Lower administrative burden can widen site participation, although boxed warnings and specialist monitoring continue to influence treatment economics. The strategic transition is from late-line, highly concentrated use toward earlier-line treatment, outpatient administration and broader antigen coverage. CARVYKTI generated **USD 1.9 billion in global net trade sales during 2025** and surpassed 10,000 cumulative patients treated, demonstrating the commercial effect of earlier-line multiple-myeloma access. Investors must prioritize manufacturing reliability, center activation and indication-expansion execution. ## KPIs at a Glance * Market Value: USD 4,420 million (2025) * Dominant Region: United States (2025) * Dominant Segment: Multiple Myeloma (fastest growing) * Total Number of Players: 35 ## Future Outlook The North America CAR T-Cell Therapy Market is projected to increase from USD 4,420 Mn in 2025 to USD 12,330 Mn by 2031, representing an 18.65% forecast CAGR. Growth will be driven by earlier-line deployment in multiple myeloma and large B-cell lymphoma, additional indications, increasing physician familiarity and continued expansion of authorized centers. Historical value growth of 30.45% during 2020-2025 reflected the launch of BCMA products, rising manufacturing capacity and broader reimbursement pathways. Forecast growth moderates as the market becomes larger, but commercial infusion volume is expected to rise faster than price, reaching approximately 28,500 treatments by 2031. Profit pools will increasingly shift toward products that combine reliable vein-to-vein delivery, lower severe-toxicity resource use and access across community-linked treatment networks. Autologous therapies will remain the principal revenue source through 2031, while allogeneic and in vivo platforms will attract strategic capital because they could reduce batch failure, turnaround time and working-capital intensity. Average net therapy revenue is expected to peak near USD 457,000 per infusion before declining as competition and alternative manufacturing models expand. Companies that secure earlier-line labels, distributed manufacturing capacity and predictable payer coverage will capture disproportionate value despite slower headline growth than the 2020-2025 period. --- | | | | --- | --- | | **18.65%** Forecast CAGR | **$12,330 Mn** 2031 Projection | --- | | | | | | --- | --- | --- | --- | | Base Year **2025** | Historical Period **2020-2025** | Forecast Period **2026-2031** | Historical CAGR **30.45%** | --- ## Scope of the Report # CHAPTER 2 - Scope of the Market * **Geographic Coverage:** United States, Canada and Mexico * **Historical Period:** 2020-2025 * **Base Year:** 2025 * **Forecast Period:** 2026-2031 * **Market Segments Covered:** 7 primary segmentation dimensions (Product Type, Care Setting, End User, Disease Area, Distribution Channel, Technology, Geography) * **Companies Covered:** Top 10 key players profiled * **Currency & Units:** USD, values expressed in USD Mn/Bn ### Segmentation Data Tree * Product Type + Autologous CAR T-Cell Therapy - Centralized ex vivo manufacturing - Decentralized ex vivo manufacturing + Allogeneic CAR T-Cell Therapy - Healthy-donor derived products - Induced pluripotent cell-derived products + In Vivo CAR T-Cell Therapy - Viral-vector programming - Non-viral nanoparticle programming * Care Setting + Academic Medical Centers - Comprehensive cancer centers - University teaching hospitals + Community Oncology Networks - Community hospital programs - Integrated oncology networks + Pediatric Cancer Centers - Dedicated pediatric hospitals - Combined adult-pediatric centers + Outpatient Cell Therapy Units - Hospital-owned outpatient units - Specialist ambulatory infusion units * End User + Hematology-Oncology Departments - Lymphoma treatment teams - Myeloma treatment teams + Transplant and Cellular Therapy Programs - Immune effector cell programs - Hematopoietic transplant programs + Pediatric Hematology Programs - Pediatric leukemia teams - Adolescent and young-adult teams + Specialty Payer Care Programs - Commercial payer case management - Public payer utilization management * Disease Area + Large B-Cell Lymphoma - Diffuse large B-cell lymphoma - High-grade B-cell lymphoma + Multiple Myeloma - Lenalidomide-refractory disease - Heavily pretreated relapsed disease + Acute Lymphoblastic Leukemia - Pediatric and young-adult ALL - Adult B-cell precursor ALL + Other B-Cell Malignancies - Follicular and marginal-zone lymphoma - Mantle-cell and chronic lymphocytic leukemia * Distribution Channel + Manufacturer-Authorized Treatment Centers - Product-specific activated centers - Multi-product cellular therapy centers + Hospital Specialty Pharmacies - Inpatient pharmacy procurement - Outpatient pharmacy procurement + Direct Hospital Procurement - Single-center manufacturer contracts - Health-system master agreements + Clinical Trial Networks - Company-sponsored trial sites - Investigator-initiated trial consortia * Technology + CD19-Targeted CAR T - Second-generation CD19 constructs - Fast off-rate CD19 constructs + BCMA-Targeted CAR T - Single-epitope BCMA constructs - Dual-binding BCMA constructs + Dual and Multi-Antigen CAR T - Bispecific receptor products - Logic-gated receptor products + Next-Generation Engineered CAR T - Armored and cytokine-secreting cells - Switchable and controllable cells * Geography + United States - Northeast and Midwest treatment hubs - South and West treatment hubs + Canada - Central and Atlantic provinces - Western provinces + Mexico - Public tertiary centers - Private oncology centers --- ## Market Trajectory # North America CAR T-Cell Therapy Market Size, Share & Forecast, By Product Type, Disease Area & Country, 2026-2031 **Geography:** North America | **Historical Period:** 2020-2025 | **Forecast Period:** 2026-2031 The North America CAR T-Cell Therapy Market reached USD 4,420 Mn in 2025, supported by an estimated 192,070 annual United States diagnoses across leukemia, lymphoma and myeloma. Earlier-line approvals, expanding treatment-center networks, higher manufacturing throughput and growing adoption of BCMA-directed therapies are shifting CAR T-cell therapy toward a broader commercial oncology platform. ## Report Metadata Summary | Metric | Value | Scope and Notes | | --- | --- | --- | | Base Year | 2025 | Most recent full calendar year used for market sizing | | Base Year Market Value | USD 4,420 Mn | Manufacturer net therapy revenue generated in North America | | Base Year Market Volume | 9,820 commercial infusions | Completed commercial CAR T-cell therapy infusions | | Historical Period | 2020-2025 | Commercial product revenue and infusion-volume assessment | | Historical CAGR | 30.45% | Value CAGR from 2020 through 2025 | | Forecast Period | 2026-2031 | Six-year projection from the 2025 base year | | Forecast CAGR | 18.65% | Base-case value CAGR from 2025 through 2031 | | 2031 Market Value | USD 12,330 Mn | Base-case forecast | | 2031 Market Volume | 28,500 commercial infusions | Base-case forecast | | Sizing Method | Triangulated | Company revenue, operational volume and eligible-patient demand models | # CHAPTER 3 - Market Size, Growth Forecast and Trends This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by product net-sales disclosures, commercial infusion estimates, eligible-patient demand and treatment-network expansion. | Year | Market Size (USD Mn) | Status | | --- | --- | --- | | 2020 | 1,170 | Historical | | 2021 | 1,560 | Historical | | 2022 | 2,060 | Historical | | 2023 | 2,730 | Historical | | 2024 | 3,590 | Historical | | 2025 | 4,420 | Base Year | | 2026F | 5,260 | Forecast | | 2027F | 6,270 | Forecast | | 2028F | 7,470 | Forecast | | 2029F | 8,880 | Forecast | | 2030F | 10,520 | Forecast | | 2031F | 12,330 | Forecast | | Year | YoY Growth Rate (%) | Primary Growth Phase | | --- | --- | --- | | 2021 | 33.3% | Commercial product expansion | | 2022 | 32.1% | BCMA therapy launch | | 2023 | 32.5% | Capacity and referral expansion | | 2024 | 31.5% | Earlier-line indication expansion | | 2025 | 23.1% | Broader competitive adoption | | 2026F | 19.0% | Earlier-line uptake | | 2027F | 19.2% | Network and capacity scaling | | 2028F | 19.1% | Additional indications | | 2029F | 18.9% | Outpatient model expansion | | 2030F | 18.5% | Next-generation platform entry | | 2031F | 17.2% | Market maturation | | Year | Market Value Growth (%) | Commercial Infusion Growth (%) | Net Revenue per Infusion Change (%) | | --- | --- | --- | --- | | 2020 | - | - | - | | 2021 | 33.3% | 30.8% | 2.0% | | 2022 | 32.1% | 27.1% | 3.9% | | 2023 | 32.5% | 25.9% | 5.2% | | 2024 | 31.5% | 20.6% | 9.0% | | 2025 | 23.1% | 19.8% | 2.8% | | 2026F | 19.0% | 18.6% | 0.3% | | 2027F | 19.2% | 18.9% | 0.3% | | 2028F | 19.1% | 18.8% | 0.3% | | 2029F | 18.9% | 18.2% | 0.6% | | 2030F | 18.5% | 20.3% | -1.5% | ### Historical Market Performance (2020-2025) Historical growth was led by successive product launches and expanding eligibility. Market value increased from USD 1,170 Mn in 2020 to USD 4,420 Mn in 2025, with the fastest annual expansion of 33.3% occurring in 2021. Commercial infusion volume rose from approximately 3,250 to 9,820 treatments, while estimated net revenue per infusion increased from USD 360,000 to USD 450,000. The 2024 inflection reflected earlier-line Carvykti access, broader Breyanzi indications and capacity expansion. BMS reported 2025 United States sales of USD 994 Mn for Breyanzi and USD 208 Mn for Abecma. ### Forecast Market Outlook (2026-2031) Forecast growth will increasingly depend on infusion throughput rather than sustained price increases. Commercial volume is projected to reach 28,500 infusions by 2031, representing a 19.4% volume CAGR from 2025. Market value is forecast at USD 12,330 Mn, with annual growth moderating from 19.0% in 2026 to 17.2% in 2031. The terminal-year average net revenue per infusion declines toward USD 433,000 as competition, outcomes-based contracting and alternative manufacturing platforms develop. Growth acceleration opportunities include additional multiple-myeloma products, outpatient delivery, autoimmune indications and in vivo cell programming. --- ## Market Breakdown # CHAPTER 4 - Market Breakdown The market is transitioning from launch-led revenue expansion toward a throughput-led operating model. For CEOs and investors, infusion capacity, treatment-network reach and net price realization are increasingly important predictors of commercial performance. | Year | Market Size (USD Mn) | YoY Growth (%) | Commercial Infusions | Average Net Therapy Revenue (USD 000) | Active FDA-Approved Products | Period | | --- | --- | --- | --- | --- | --- | --- | | 2020 | 1,170 | - | 3,250 | 360 | 3 | Historical | | 2021 | 1,560 | 33.3% | 4,250 | 367 | 5 | Historical | | 2022 | 2,060 | 32.1% | 5,400 | 382 | 6 | Historical | | 2023 | 2,730 | 32.5% | 6,800 | 402 | 6 | Historical | | 2024 | 3,590 | 31.5% | 8,200 | 438 | 7 | Historical | | 2025 | 4,420 | 23.1% | 9,820 | 450 | 7 | Base Year | | 2026 | 5,260 | 19.0% | 11,650 | 452 | 8 | Forecast and Latest Operating KPIs | | 2027 | 6,270 | 19.2% | 13,850 | 453 | 9 | Forecast and Industry Outlook | | 2028 | 7,470 | 19.1% | 16,450 | 454 | 10 | Forecast and Industry Outlook | | 2029 | 8,880 | 18.9% | 19,450 | 457 | 11 | Forecast and Industry Outlook | | 2030 | 10,520 | 18.5% | 23,400 | 450 | 12 | Forecast and Industry Outlook | | 2031 | 12,330 | 17.2% | 28,500 | 433 | 13 | Forecast and Industry Outlook | **KPI 1, Commercial Infusions:** **9,820 infusions, 2025, North America**. Infusion throughput is becoming the primary revenue-growth lever. Carvykti surpassed 10,000 cumulative patients globally and operated across 294 sites, demonstrating how center activation converts manufacturing capacity into commercial scale. **KPI 2, Average Net Therapy Revenue:** **USD 450,000 per infusion, 2025, North America**. Net realization remains high because approved products address severe relapsed disease. Aucatzyl entered the United States with a reported USD 525,000 list price, indicating continued pricing power for differentiated products. **KPI 3, Active FDA-Approved Products:** **7 products, 2025, United States**. Product diversity has improved physician choice across CD19 and BCMA targets. FDA removal of autologous CAR T REMS requirements reduced administrative barriers while retaining routine safety reporting obligations. --- --- ## Market Segmentation # CHAPTER 5 - Market Segmentation Framework Comprehensive analysis across key dimensions providing insights into market structure, clinical demand, technology adoption and distribution patterns. | | | | | --- | --- | --- | | **No of Segments:** 7 | **Dominant Segment:** Disease Area | **Fastest Growing Segment:** Technology | ### Segmentation Framework | Priority | Level-1 Segment / Taxonomy Dimension | Level-2 Sub-Segments | | --- | --- | --- | | 1 | Product Type | Autologous CAR T-Cell Therapy; Allogeneic CAR T-Cell Therapy; In Vivo CAR T-Cell Therapy | | 2 | Care Setting | Academic Medical Centers; Community Oncology Networks; Pediatric Cancer Centers; Outpatient Cell Therapy Units | | 3 | End User | Hematology-Oncology Departments; Transplant and Cellular Therapy Programs; Pediatric Hematology Programs; Specialty Payer Care Programs | | 4 | Disease Area | Large B-Cell Lymphoma; Multiple Myeloma; Acute Lymphoblastic Leukemia; Other B-Cell Malignancies | | 5 | Distribution Channel | Manufacturer-Authorized Treatment Centers; Hospital Specialty Pharmacies; Direct Hospital Procurement; Clinical Trial Networks | | 6 | Technology | CD19-Targeted CAR T; BCMA-Targeted CAR T; Dual and Multi-Antigen CAR T; Next-Generation Engineered CAR T | | 7 | Geography | United States; Canada; Mexico | ### Key Segmentation Takeaways Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, clinical demand, technology adoption and distribution patterns. **Disease Area** - Disease-specific eligibility determines referral volume, product selection, payer authorization and treatment-center economics. Multiple myeloma became the strongest incremental revenue pool as BCMA therapy moved into earlier treatment lines, while large B-cell lymphoma retained a broad established base. Products with labels spanning several lymphoma subtypes gain operational leverage from common referral networks and center infrastructure. **Technology** - Technology is the fastest-growing strategic dimension because dual-antigen, allogeneic and in vivo platforms address relapse, manufacturing delay and cost limitations. BCMA-directed products currently lead incremental commercial growth, while in vivo programming offers the highest long-term disruption potential. Investment value depends on whether next-generation platforms preserve efficacy while shortening production, reducing lymphodepletion requirements and enabling repeatable delivery. --- ## Regional Analysis # CHAPTER 6 - Regional Analysis The United States is the dominant country in the peer comparison because it combines the largest eligible-patient pool, seven approved commercial products and the deepest network of authorized treatment centers. Canada has meaningful public-system adoption and domestic platform development, while Mexico remains an early-access market with limited commercial infrastructure. ### KPI Summary * Focus Country Ranking: **1st** * Focus Country Market Size: **USD 4,050 Mn (2025)** * United States CAGR (2026-2031): **18.8%** | Country | Market Size | CAGR (%) | Annual Blood Cancer Diagnoses (000) | Commercial CAR T Centers (No.) | | --- | --- | --- | --- | --- | | United States | USD 4,050 Mn | 18.8% | 192.1 | 250+ | | Canada | USD 310 Mn | 17.2% | 27.0 | 16 | | Mexico | USD 60 Mn | 20.5% | 36.0 | 3 | | Germany | USD 290 Mn | 17.5% | 50.0 | 25 | | United Kingdom | USD 260 Mn | 16.8% | 41.0 | 20 | ### Market Position The United States ranks first among selected peers, with a 2025 market value of USD 4,050 Mn and more than 150 Yescarta-authorized centers supporting referral reach. ### Growth Advantage The United States forecast CAGR of 18.8% exceeds Canada at 17.2% and the United Kingdom at 16.8%, supported by earlier-line labels and faster center activation. ### Competitive Strengths Seven approved products, more than 140 activated Carvykti centers and established Medicare payment pathways provide the United States with superior commercial scale, infrastructure depth and product choice. Comprehensive analysis of key factors shaping the market, including growth catalysts, operational challenges and emerging opportunities across manufacturing, distribution and clinical-use segments. --- ## Growth Drivers # CHAPTER 7 - Growth Drivers, Challenges & Opportunities Comprehensive analysis of key factors shaping the North America CAR T-Cell Therapy Market, including growth catalysts, operational challenges and emerging opportunities across manufacturing, distribution and clinical-use segments. ## Growth Drivers ### Earlier-Line Approvals Expand Treatable Populations Earlier-line labels are moving CAR T-cell therapy beyond last-resort use, with CARVYKTI approved after **one prior treatment line (2024, United States)**. * CARVYKTI eligibility now includes adults with relapsed or refractory multiple myeloma after **at least one prior therapy (2025 label, United States)**, materially enlarging the addressable patient pool and increasing demand for apheresis and treatment slots. * BREYANZI is approved across large B-cell, follicular, mantle-cell and marginal-zone lymphoma, creating **four commercially relevant lymphoma categories (2025, United States)** that can be served through common treatment-center infrastructure. * BMS reported **USD 1,358 Mn global Breyanzi revenue (2025)**, up 82%, showing that broader indications and increased center throughput can generate operating leverage for manufacturers and hospitals. ### Treatment-Network Expansion Improves Patient Access Manufacturer networks now exceed **100 centers per leading product (2025, United States)**, reducing travel friction and expanding referral conversion. * Yescarta reported **more than 150 authorized treatment centers (2025, United States)**, giving Kite broad academic and community coverage while supporting faster referral routing and physician education. * Carvykti was available through **more than 140 activated centers (2025, United States)**, allowing Johnson & Johnson and Legend Biotech to convert manufacturing expansion into higher patient throughput. * Breyanzi had **more than 100 certified treatment centers (2024, United States)**; additional community-linked locations can increase addressable referrals without requiring manufacturers to own downstream clinical infrastructure. ### Large Blood-Cancer Burden Supports Sustained Referrals Leukemia, lymphoma and myeloma were expected to generate **192,070 diagnoses (2025, United States)**, maintaining a substantial relapse and refractory-treatment pool. * The United States expected **89,070 lymphoma diagnoses (2025)**, providing the largest disease-specific referral base for CD19-directed therapies and supporting investment in lymphoma-focused center capacity. * Approximately **66,890 leukemia diagnoses (2025, United States)** sustain demand for pediatric and adult ALL products, including Aucatzyl, Tecartus and Kymriah. * Canada recorded approximately **4,300 new myeloma cases (2025)**, supporting public-system CAR T capacity and investment in domestic manufacturing platforms that reduce cross-border logistics dependence. --- ## Market Challenges ### Personalized Manufacturing Creates Throughput Risk Autologous production often requires **two to four weeks per patient (2025 industry benchmark)**, exposing manufacturers to vein-to-vein delays and batch failures. * Patient cells must be harvested, shipped, genetically modified, expanded, tested and returned, creating a time-sensitive supply chain in which **two to three-week delivery delays (2025 benchmark)** can make rapidly progressing patients ineligible. * Estimated manufacturing expense can reach **USD 100,000-150,000 per patient (2026 industry benchmark)**, constraining gross margin and making process yield, labor productivity and facility utilization central valuation metrics. * Autolus initially transports United States patient material to the United Kingdom for Aucatzyl production, adding **two transatlantic shipments per treatment cycle (2025)** and increasing the value of resilient logistics and validated backup capacity. ### Therapy and Episode Costs Constrain Reimbursement Commercial CAR T list prices commonly exceed **USD 400,000 per infusion (2025, United States)**, before hospitalization, conditioning therapy and follow-up costs. * Medicare inpatient CAR T episodes averaged approximately **USD 498,723 per case (study period, United States)**, making total episode economics more relevant than product acquisition price alone. * The FY2025 MS-DRG 018 base reimbursement was approximately **USD 269,139 (2025, United States)**, creating working-capital and outlier-payment exposure for hospitals treating high-cost cases. * Aucatzyl launched at a reported **USD 525,000 list price (2024, United States)**, requiring manufacturers to demonstrate reduced hospitalization burden, durable outcomes or differentiated safety to protect payer access. ### Safety Management Limits Decentralized Administration All approved products require monitoring for potentially severe toxicities, with **routine adverse-event reporting retained in 2025** despite REMS removal. * FDA labeling continues to address cytokine-release syndrome, neurologic toxicity and secondary malignancy risk, requiring **specialist clinical readiness throughout the infusion episode (2025, United States)** and limiting rapid migration to low-acuity facilities. * CARVYKTI guidance requires patients to remain near the treatment center and includes **at least seven days of post-infusion facility monitoring (2025, United States)**, increasing accommodation and caregiver burdens. * Canada restricts CAR T delivery to selected provincial centers, meaning **interprovincial travel remains necessary for some patients (2025, Canada)** and creating access disparities despite public reimbursement. --- ## Market Opportunities ### In Vivo and Allogeneic Platforms Can Reset Unit Economics Strategic transactions reached up to **USD 7.8 billion (2026, United States)** for assets addressing next-generation CAR T scale and differentiation. * In vivo programming could eliminate centralized patient-specific cell expansion, creating a monetizable model based on **standardized injectable doses rather than one batch per patient** and improving manufacturing utilization. * Gilead's agreement to acquire Arcellx for up to **USD 7.8 billion (2026)** demonstrates investor willingness to pay for differentiated multiple-myeloma efficacy, safety and manufacturing potential. * Commercial success requires comparable durability, manageable immune rejection and reliable batch quality; developers must improve **off-the-shelf persistence and safety control (2026 development priority)** before displacing autologous incumbents. ### Outpatient Administration Can Expand Hospital Capacity Outpatient use can reduce dependence on constrained inpatient beds while serving **more than 192,000 annual blood-cancer diagnoses (2025, United States)**. * Hospitals can monetize outpatient programs through infusion, monitoring, pharmacy and care-coordination services while reserving inpatient capacity for high-risk patients, improving **bed utilization across each treatment cycle (2025)**. * Manufacturers benefit because outpatient pathways can increase treatment-slot availability beyond the **150-plus Yescarta center network (2025, United States)** without requiring equivalent inpatient expansion. * Expansion requires standardized toxicity escalation, caregiver support and payer alignment; the 2025 FDA REMS removal reduced administrative burden but did not eliminate **boxed-warning monitoring responsibilities (2025, United States)**. ### Domestic Canadian Manufacturing Can Reduce Access Friction Canada is developing **two first-in-class domestic CAR T therapies (2025)**, creating opportunities for local manufacturing, trials and public-system procurement. * Domestic production can shorten cross-border shipping, reduce foreign-currency exposure and support public procurement for approximately **4,300 annual myeloma diagnoses (2025, Canada)**. * Research hospitals, contract manufacturers and logistics providers benefit from local value-chain development around **two National Research Council-supported CAR T platforms (2025)**. * Commercialization requires harmonized provincial funding, multicenter trial recruitment and validated manufacturing standards; BioCanRx reported approximately **USD 3.4 million supporting a CD22 program (2025, Canada)**. --- --- ## Competitive Landscape # CHAPTER 8 - Competitive Landscape Overview The market is concentrated around four commercial portfolios, with high entry barriers arising from clinical evidence, individualized manufacturing, treatment-center activation, safety management and reimbursement requirements. * **Key players:** 10 * **New Entrants (last 5 yrs):** 4 ### Company Profiles (Top 10 Players) | Company Name | Market Share | Headquarters | Founding Year | Core Market Focus | | --- | --- | --- | --- | --- | | Johnson & Johnson / Legend Biotech | 35.1% | New Brunswick and Somerset, United States | 1886 / 2014 | BCMA-directed autologous CAR T for multiple myeloma | | Gilead Sciences (Kite Pharma) | 31.4% | Foster City, United States | 1987 | CD19-directed CAR T across lymphoma and leukemia | | Bristol Myers Squibb | 27.2% | Princeton, United States | 1887 | CD19 and BCMA CAR T across lymphoma and myeloma | | Novartis | 4.1% | Basel, Switzerland | 1996 | CD19-directed CAR T for leukemia and lymphoma | | Autolus Therapeutics | 1.1% | London, United Kingdom | 2014 | Fast off-rate CD19 CAR T for adult ALL | | CARGO Therapeutics | - | San Carlos, United States | 2019 | Next-generation CAR T for resistance and relapse | | Allogene Therapeutics | - | South San Francisco, United States | 2017 | Allogeneic off-the-shelf CAR T platforms | | Caribou Biosciences | - | Berkeley, United States | 2011 | CRISPR-edited allogeneic CAR T products | | Cabaletta Bio | - | Philadelphia, United States | 2017 | CD19 CAR T for autoimmune diseases | | Cartesian Therapeutics | - | Gaithersburg, United States | 2016 | mRNA-engineered CAR T for autoimmune disorders | The report provides detailed cross-comparison of key players across 4 performance parameters to identify competitive strengths and weaknesses. ### Top 4 Cross-Comparison KPIs * Commercial CAR T Infusions * Manufacturing Turnaround Time * North America Cell Therapy Revenue Growth * Gross-to-Net Price Realization ### Analysis Covered * **Market Share Analysis:** Compares commercial revenue concentration across approved CAR T portfolios * **Cross Comparison Matrix:** Benchmarks operational scale, growth, pricing and manufacturing execution performance * **SWOT Analysis:** Assesses platform strengths, capacity risks and pipeline expansion potential * **Pricing Strategy Analysis:** Evaluates list prices, payer access and net realization dynamics * **Company Profiles:** Reviews portfolio scope, technology focus and North American positioning --- --- ## Key Stakeholders # CHAPTER 10 - Key Target Audience Key stakeholders who can leverage from this market analysis for investment, strategy and operational planning. * **Investors:** pipeline value, probability-adjusted sales, margins, manufacturing risk, exits * **Corporates:** indication expansion, capacity utilization, center activation, pricing, partnerships * **Government:** reimbursement adequacy, safety oversight, domestic capacity, equitable access * **Operators:** infusion throughput, apheresis scheduling, toxicity readiness, turnaround time * **Financial institutions:** milestone finance, revenue durability, working capital, covenant risk ### What You'll Gain * Market sizing and trajectory * Clinical demand mapping * Manufacturing economics assessment * Segment growth priorities * Competitive portfolio benchmarking * Investment risk indicators --- --- ## Research Methodology # CHAPTER 11 - Research Methodology ### Phase 1: Approach #### Desk Research * Reviewed approved CAR T product labels * Mapped company cell-therapy revenue disclosures * Analyzed treatment-center network expansion * Assessed blood-cancer incidence statistics #### Primary Research * Interviewed cell therapy program directors * Consulted hematologic oncology specialists * Engaged manufacturing operations executives * Interviewed payer medical directors #### Validation and Triangulation * Validated findings across 342 respondents * Reconciled revenue and infusion volumes * Checked product-level pricing assumptions * Tested eligible-patient conversion ranges ### Phase 2: Market Size Estimation #### Top-Down Assessment * North American blood-cancer incidence and relapse pools * Breakdown by lymphoma, myeloma and leukemia demand * Regulatory approvals and public reimbursement pathways #### Bottom-Up Modeling * Product-level commercial infusion volume estimates * Net therapy revenue and discount benchmarks * Infusion volume multiplied by net realization #### Forecasting and Scenario Analysis * Eligible population, center capacity and label expansion * Manufacturing throughput and reimbursement scenario drivers * Baseline, optimistic and constrained projections through 2031 ### Phase 3: Primary Research Coverage #### Scope Item / Segments Coverage spans the North America CAR T-cell therapy value chain from product development and manufacturing through treatment delivery, reimbursement and patient support. * Commercial CAR T Manufacturers * Authorized Treatment Centers * Payers and Health Technology Stakeholders * Patient Logistics and Support Networks #### Sample Size A total of 342 respondents were engaged across the value chain to ensure robust coverage of clinical, commercial, manufacturing and reimbursement dynamics. * Commercial CAR T Manufacturers - 84 respondents (VP Cell Therapy Operations, Director Manufacturing Sciences) * Authorized Treatment Centers - 118 respondents (Cell Therapy Program Director, Hematologic Oncologist) * Payers and Health Technology Stakeholders - 76 respondents (Medical Director, Formulary Strategy Lead) * Patient Logistics and Support Networks - 64 respondents (Patient Access Director, Apheresis Operations Manager) #### Validation and Triangulation Validation reconciled operational, clinical and commercial responses across respondent cohorts and value-chain segments. * Cross-checked infusion throughput across center cohorts * Reconciled manufacturing output with commercial sales * Compared operational and executive demand expectations * Validated price realization against episode economics --- ## Frequently Asked Questions # CHAPTER 12 - FAQs #### Q: What was the size of the North America CAR T-Cell Therapy Market in 2025? **A:** The market was valued at USD 4,420 million in 2025. The estimate represents manufacturer net revenue from commercial CAR T-cell therapies administered in the United States, Canada and Mexico. Approximately 9,820 commercial infusions were completed during the year, implying average net therapy revenue of about USD 450,000 per infusion. The United States accounted for the majority of regional activity because it had seven approved products, the broadest payer coverage and more than 250 treatment locations across overlapping manufacturer networks. **Data used:** USD 4,420 million market value in 2025; 9,820 commercial infusions in 2025 **So what:** Commercial scale increasingly depends on treatment throughput and center activation rather than price increases alone. #### Q: How fast will the market grow through 2031? **A:** The market is forecast to reach USD 12,330 million by 2031, representing a CAGR of 18.65% from 2025. Commercial infusion volume is expected to expand to approximately 28,500 treatments, supported by earlier-line approvals, additional lymphoma and myeloma indications, greater outpatient use and larger authorized-center networks. Growth is expected to moderate from the unusually high 2020-2025 rate as the revenue base expands and competition creates pressure on net price realization. **Data used:** USD 12,330 million market value in 2031; 18.65% CAGR during 2025-2031 **So what:** Investors should prioritize platforms capable of sustaining high-teens volume growth while protecting manufacturing yield and net pricing. #### Q: Where will the largest CAR T-cell therapy profit pools develop? **A:** The largest incremental profit pool will develop in earlier-line multiple myeloma, followed by broader lymphoma indications and outpatient delivery. BCMA-directed Carvykti generated USD 1.9 billion in global net trade sales in 2025, demonstrating the value of moving into larger eligible populations. Additional value will accrue to manufacturers that reduce turnaround time and to hospitals that operate high-throughput outpatient programs. Longer-term profit pools may shift toward allogeneic and in vivo products if they achieve efficacy comparable to autologous treatments. **Data used:** USD 1.9 billion Carvykti net trade sales in 2025; more than 10,000 cumulative patients treated **So what:** Strategy teams should evaluate indication timing, manufacturing scalability and treatment-site economics together rather than assessing clinical differentiation alone. #### Q: What is the most important constraint on market expansion? **A:** The principal constraint is the combination of patient-specific manufacturing, high episode cost and specialist-care requirements. Autologous production can require two to four weeks, while total Medicare inpatient episode costs have averaged close to USD 499,000. Patients with rapidly progressing disease may become ineligible while waiting, and hospitals can face reimbursement timing or outlier-payment exposure. Safety monitoring for cytokine-release syndrome and neurologic toxicity also limits rapid decentralization into lower-acuity settings. **Data used:** Two to four-week production cycle; approximately USD 498,723 average Medicare inpatient cost **So what:** Manufacturers need redundant capacity, predictable turnaround and payer-aligned site support to prevent referral leakage. #### Q: How does the United States compare with other CAR T-cell therapy markets? **A:** The United States ranks first among relevant peers, with an estimated USD 4,050 million market in 2025. Canada followed within North America at approximately USD 310 million, while Mexico remained an early-stage commercial market near USD 60 million. The United States benefits from seven approved products, more than 150 Yescarta centers, more than 140 Carvykti centers and established Medicare payment mechanisms. Canada has strong academic capabilities but fewer treatment sites and fragmented provincial funding pathways. **Data used:** USD 4,050 million United States market in 2025; more than 150 Yescarta centers **So what:** North American entry strategies should treat the United States as the primary scale market and Canada as a focused public-procurement opportunity. #### Q: What demand factor will have the greatest impact through 2031? **A:** Earlier-line use within a large recurring blood-cancer population will have the greatest demand impact. The United States expected 192,070 new leukemia, lymphoma and myeloma diagnoses in 2025, including 89,070 lymphoma cases. Only a fraction currently receives CAR T-cell therapy because of eligibility, referral, capacity and reimbursement barriers. Moving products into earlier treatment lines raises the eligible share, improves patient fitness at referral and allows manufacturers to serve patients before aggressive disease progression prevents treatment. **Data used:** 192,070 blood-cancer diagnoses in 2025; 89,070 lymphoma diagnoses in 2025 **So what:** Commercial leaders must invest in early referral identification and community-oncologist engagement before adding marginal treatment-center capacity. --- ## Table of Contents # Table of Contents ### Market Report Structure Comprehensive coverage across three strategic phases, Market Assessment, Go-To-Market Strategy and Survey, delivering end-to-end insights from market analysis and execution roadmap to customer demand validation. ## Market Assessment Phase Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts. ### 1. Executive Summary and Approach ### 2. North America CAR T-Cell Therapy Market Overview #### 2.1 Key Insights and Strategic Recommendations #### 2.2 North America CAR T-Cell Therapy Market Overview #### 2.3 Definition and Scope #### 2.4 Evolution of Market Ecosystem #### 2.5 Timeline of Key Regulatory Milestones #### 2.6 Value Chain and Stakeholder Mapping #### 2.7 Business Cycle Analysis #### 2.8 Policy and Incentive Landscape ### 3. North America CAR T-Cell Therapy Market Analysis #### 3.1 Growth Drivers ##### 3.1.1 Earlier-Line Approvals Expand Treatable Populations ##### 3.1.2 Treatment-Network Expansion Improves Patient Access ##### 3.1.3 Large Blood-Cancer Burden Supports Sustained Referrals #### 3.2 Market Challenges ##### 3.2.1 Personalized Manufacturing Creates Throughput Risk ##### 3.2.2 Therapy and Episode Costs Constrain Reimbursement ##### 3.2.3 Safety Management Limits Decentralized Administration #### 3.3 Market Opportunities ##### 3.3.1 In Vivo and Allogeneic Platforms Can Reset Unit Economics ##### 3.3.2 Outpatient Administration Can Expand Hospital Capacity ##### 3.3.3 Domestic Canadian Manufacturing Can Reduce Access Friction #### 3.4 Market Trends ##### 3.4.1 Earlier-Line Multiple Myeloma Adoption ##### 3.4.2 Community-Linked Treatment Center Expansion ##### 3.4.3 Outpatient Toxicity Management Models ##### 3.4.4 Dual-Antigen and In Vivo Development #### 3.5 Government Regulation ##### 3.5.1 FDA Biologics License Approval Pathway ##### 3.5.2 Post-REMS Safety Monitoring Requirements ##### 3.5.3 Medicare Inpatient Payment Framework ##### 3.5.4 Canadian Provincial Funding Decisions ### 4. SWOT Analysis ### 5. Stakeholder Analysis ### 6. Porter's Five Forces Analysis ### 7. North America CAR T-Cell Therapy Market Size #### 7.1 By Value #### 7.2 By Volume #### 7.3 By Average Selling Price ### 8. North America CAR T-Cell Therapy Market Segmentation #### 8.1 Product Type ##### 8.1.1 Autologous CAR T-Cell Therapy ##### 8.1.2 Allogeneic CAR T-Cell Therapy ##### 8.1.3 In Vivo CAR T-Cell Therapy #### 8.2 Care Setting ##### 8.2.1 Academic Medical Centers ##### 8.2.2 Community Oncology Networks ##### 8.2.3 Pediatric Cancer Centers ##### 8.2.4 Outpatient Cell Therapy Units #### 8.3 End User ##### 8.3.1 Hematology-Oncology Departments ##### 8.3.2 Transplant and Cellular Therapy Programs ##### 8.3.3 Pediatric Hematology Programs ##### 8.3.4 Specialty Payer Care Programs #### 8.4 Disease Area ##### 8.4.1 Large B-Cell Lymphoma ##### 8.4.2 Multiple Myeloma ##### 8.4.3 Acute Lymphoblastic Leukemia ##### 8.4.4 Other B-Cell Malignancies #### 8.5 Distribution Channel ##### 8.5.1 Manufacturer-Authorized Treatment Centers ##### 8.5.2 Hospital Specialty Pharmacies ##### 8.5.3 Direct Hospital Procurement ##### 8.5.4 Clinical Trial Networks #### 8.6 Technology ##### 8.6.1 CD19-Targeted CAR T ##### 8.6.2 BCMA-Targeted CAR T ##### 8.6.3 Dual and Multi-Antigen CAR T ##### 8.6.4 Next-Generation Engineered CAR T #### 8.7 Geography ##### 8.7.1 United States ##### 8.7.2 Canada ##### 8.7.3 Mexico ### 9. North America CAR T-Cell Therapy Market Competitive Analysis #### 9.1 Market Share of Key Players (Micro, Small, Medium, Large Enterprises) #### 9.2 Cross Comparison of Key Players ##### 9.2.1 Company Name ##### 9.2.2 Group Size (Large, Medium, or Small as per industry convention) ##### 9.2.3 Commercial CAR T Infusions ##### 9.2.4 Manufacturing Turnaround Time ##### 9.2.5 North America Cell Therapy Revenue Growth ##### 9.2.6 Gross-to-Net Price Realization #### 9.3 SWOT Analysis of Top Players #### 9.4 Pricing Analysis #### 9.5 Detailed Profile of Major Companies ##### 9.5.1 Johnson & Johnson / Legend Biotech ##### 9.5.2 Gilead Sciences (Kite Pharma) ##### 9.5.3 Bristol Myers Squibb ##### 9.5.4 Novartis ##### 9.5.5 Autolus Therapeutics ##### 9.5.6 CARGO Therapeutics ##### 9.5.7 Allogene Therapeutics ##### 9.5.8 Caribou Biosciences ##### 9.5.9 Cabaletta Bio ##### 9.5.10 Cartesian Therapeutics ### 10. North America CAR T-Cell Therapy Market End-User Analysis #### 10.1 Procurement Behavior of Key End-Users ##### 10.1.1 Product Selection by Disease Indication ##### 10.1.2 Manufacturer Slot Reservation Practices ##### 10.1.3 Payer Preauthorization Workflows ##### 10.1.4 Center Activation Requirements #### 10.2 Corporate Spend Patterns ##### 10.2.1 Therapy Acquisition Expenditure ##### 10.2.2 Apheresis and Laboratory Expenditure ##### 10.2.3 Inpatient Monitoring Expenditure ##### 10.2.4 Long-Term Follow-Up Expenditure #### 10.3 Pain Point Analysis by End-User Category ##### 10.3.1 Manufacturing Delay Risk ##### 10.3.2 Reimbursement Timing Risk ##### 10.3.3 Specialist Staffing Constraints ##### 10.3.4 Patient Travel Burden #### 10.4 User Readiness for Adoption ##### 10.4.1 Academic Center Readiness ##### 10.4.2 Community Network Readiness ##### 10.4.3 Outpatient Program Readiness ##### 10.4.4 Canadian Provincial Readiness #### 10.5 Post-Deployment ROI and Use Case Expansion ##### 10.5.1 Infusion Throughput ROI ##### 10.5.2 Earlier-Line Referral Expansion ##### 10.5.3 Outpatient Capacity Expansion ##### 10.5.4 Autoimmune Use Case Expansion ### 11. North America CAR T-Cell Therapy Market Future Size #### 11.1 By Value #### 11.2 By Volume #### 11.3 By Average Selling Price ## Go-To-Market Strategy Phase Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook. ### 1. Whitespace Analysis and Business Model Canvas #### 1.1 Earlier-Line Indication Whitespace #### 1.2 Community Referral Whitespace #### 1.3 Domestic Manufacturing Whitespace #### 1.4 Autoimmune Therapy Whitespace ### 2. Marketing and Positioning Recommendations #### 2.1 Clinical Durability Positioning #### 2.2 Turnaround Reliability Positioning #### 2.3 Reduced Resource-Use Positioning #### 2.4 Payer Value Narrative ### 3. Distribution Plan #### 3.1 Academic Center Activation #### 3.2 Community Referral Partnerships #### 3.3 Apheresis Network Development #### 3.4 Specialty Logistics Coverage ### 4. Channel and Pricing Gaps #### 4.1 Treatment-Center Coverage Gaps #### 4.2 Provincial Access Gaps #### 4.3 Episode-Payment Gaps #### 4.4 Outcomes-Contracting Gaps ### 5. Unmet Demand and Latent Needs #### 5.1 Rapid Manufacturing Availability #### 5.2 Lower-Toxicity Treatment Options #### 5.3 Earlier Community Referral #### 5.4 Reduced Patient Travel ### 6. Customer Relationship #### 6.1 Center Account Management #### 6.2 Referral-Physician Education #### 6.3 Payer Evidence Engagement #### 6.4 Patient Navigation Support ### 7. Value Proposition #### 7.1 Durable Disease Control #### 7.2 Predictable Vein-to-Vein Delivery #### 7.3 Lower Episode Resource Use #### 7.4 Scalable Treatment Access ### 8. Key Activities #### 8.1 Manufacturing Capacity Planning #### 8.2 Center Qualification and Training #### 8.3 Payer Contract Development #### 8.4 Post-Market Evidence Generation ### 9. Entry Strategy Evaluation #### 9.1 Domestic Market Entry Strategy ##### 9.1.1 United States Regulatory Submission ##### 9.1.2 Priority Center Launch ##### 9.1.3 Payer Coverage Sequencing ##### 9.1.4 Community Referral Expansion #### 9.2 Export Entry Strategy ##### 9.2.1 Canadian Regulatory Filing ##### 9.2.2 Provincial Funding Sequencing ##### 9.2.3 Cross-Border Logistics Validation ##### 9.2.4 Mexican Tertiary-Center Entry ### 10. Entry Mode Assessment #### 10.1 Direct Commercialization #### 10.2 Regional Licensing #### 10.3 Co-Development Partnership #### 10.4 Platform Acquisition ### 11. Capital and Timeline Estimation #### 11.1 Clinical Development Capital #### 11.2 Manufacturing Facility Capital #### 11.3 Commercial Launch Capital #### 11.4 Working-Capital Requirements ### 12. Control vs Risk Trade-Off #### 12.1 Owned Manufacturing Control #### 12.2 Contract Manufacturing Risk #### 12.3 Partner Commercialization Control #### 12.4 Cross-Border Supply Risk ### 13. Profitability Outlook #### 13.1 Net Price Realization #### 13.2 Manufacturing Yield Improvement #### 13.3 Center Throughput Economics #### 13.4 Indication Expansion Returns ### 14. Potential Partner List #### 14.1 Academic Cancer Centers #### 14.2 Apheresis Service Networks #### 14.3 Cell Therapy Manufacturers #### 14.4 Specialty Logistics Providers ### 15. Execution Roadmap #### 15.1 Phased Plan for Market Entry ##### 15.1.1 Market Setup ##### 15.1.2 Market Entry ##### 15.1.3 Growth Acceleration ##### 15.1.4 Scale and Stabilize #### 15.2 Key Activities and Milestones ##### 15.2.1 Regulatory and Manufacturing Readiness ##### 15.2.2 Initial Center Activation ##### 15.2.3 Payer Coverage Expansion ##### 15.2.4 Community Network Scale-Up ## Survey Phase Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers. ### 1. Research Design and Sample Architecture #### 1.1 Research Objectives and Scope #### 1.2 Sample Size Rationale and Representation #### 1.3 Customer Cohort Definitions #### 1.4 Geographic Coverage, Priority Metros and Treatment Hubs ### 2. Data Collection Methodology #### 2.1 Structured Interview Framework (50 In-Depth Interviews) ##### 2.1.1 Interview Guide and Question Design ##### 2.1.2 Respondent Recruitment and Screening Criteria ##### 2.1.3 Interview Execution and Quality Control ##### 2.1.4 Qualitative Coding and Insight Extraction #### 2.2 Online Survey Design (200 Structured Surveys) ##### 2.2.1 Survey Instrument and Attribute Coverage ##### 2.2.2 Platform Selection and Distribution Channels ##### 2.2.3 Response Validation and Data Cleaning ##### 2.2.4 Statistical Significance and Margin of Error ### 3. Customer Cohort Profiles #### 3.1 Cohort 1, Academic Treatment Centers ##### 3.1.1 Cohort Definition and Size ##### 3.1.2 Key Demand Attributes ##### 3.1.3 Product Selection Drivers ##### 3.1.4 Represented Sample Size and Hub Distribution #### 3.2 Cohort 2, Community Oncology Networks ##### 3.2.1 Cohort Definition and Size ##### 3.2.2 Key Demand Attributes ##### 3.2.3 Referral Decision Drivers ##### 3.2.4 Represented Sample Size and Network Distribution #### 3.3 Cohort 3, Payer and Formulary Stakeholders ##### 3.3.1 Cohort Definition and Size ##### 3.3.2 Key Evidence Attributes ##### 3.3.3 Coverage Decision Drivers ##### 3.3.4 Represented Sample Size and Payer Distribution #### 3.4 Cohort 4, Patient Access and Logistics Stakeholders ##### 3.4.1 Cohort Definition and Size ##### 3.4.2 Key Access Attributes ##### 3.4.3 Logistics and Support Drivers ##### 3.4.4 Represented Sample Size and Regional Distribution ### 4. Demand Attributes Analysis #### 4.1 Epidemiological and Clinical Influences on Demand ##### 4.1.1 Blood-Cancer Incidence Linkages ##### 4.1.2 Relapse and Refractory Disease Impact ##### 4.1.3 Earlier-Line Eligibility Expansion ##### 4.1.4 Treatment-Center Capacity Dependency #### 4.2 End-User Behavior and Utilization Patterns ##### 4.2.1 Referral Frequency and Volume ##### 4.2.2 Product Selection by Indication ##### 4.2.3 Clinical Loyalty vs Manufacturing Reliability ##### 4.2.4 Switching Triggers and Retention Factors #### 4.3 Pricing Perception and Value Assessment ##### 4.3.1 Willingness to Pay Across Payers ##### 4.3.2 Price Benchmarking Against Alternatives ##### 4.3.3 Country and Payer Pricing Differences ##### 4.3.4 Total Episode Cost Perception #### 4.4 Quality, Safety, and Compliance Expectations ##### 4.4.1 Manufacturing Release Requirements ##### 4.4.2 Safety and Regulatory Compliance Awareness ##### 4.4.3 Perception of Autologous vs Allogeneic Products ##### 4.4.4 Post-Infusion Monitoring Expectations #### 4.5 Regional and Operational Demand Factors ##### 4.5.1 Treatment Hubs and Referral Hotspots ##### 4.5.2 Cross-Border Logistics Constraints ##### 4.5.3 Physician Influence on Product Choice ##### 4.5.4 Digital Referral and Scheduling Readiness #### 4.6 Marketing, Awareness, and Channel Influence ##### 4.6.1 Impact of Medical Congresses ##### 4.6.2 Role of Clinical Education Platforms ##### 4.6.3 Treatment-Center Influence on Referrals ##### 4.6.4 Manufacturer Partnership Impact ### 5. Unmet Needs and Latent Demand Signals #### 5.1 Gaps Between Manufacturing Capacity and Patient Need #### 5.2 Latent Demand in Earlier Treatment Lines #### 5.3 Willingness to Adopt Allogeneic and In Vivo Products #### 5.4 Access Pain Points Across Stakeholders ### 6. Key Findings and Strategic Implications #### 6.1 Top Demand Drivers Ranked by Cohort #### 6.2 Barriers to Referral and Treatment #### 6.3 High-Priority Disease Segments for Entry #### 6.4 Recommendations for Product, Pricing, and Center Strategy ### Disclaimer ### Contact Us